Trial Profile

Randomised Phase 3 Study of Rituximab in High-Risk Patients With Diffuse Large B-Cell Lymphoma Who Received a First-Line Consolidative Chemotherapy With Autologous Stem Cell Transplant (ASCT)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Etoposide; Folinic acid; Methotrexate; Mitoxantrone; Prednisone; Vincristine
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use

Most Recent Events

04 Jun 2010 Quality-of-life analysis presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
01 Dec 2009 Primary endpoint 'Event free survival' has not been met.
01 Dec 2009 Results reported in the Annals of Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com